Sycamore Labs | $65,000,000 | (Mar 31, 2026)
Deccan AI | $25,000,000 | (Mar 31, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)
Certified by Founder
Lodge
Endogenex
start up
United States
- PLYMOUTH, MN
- 26/06/2024
- Series C
- $88,000,000
Endogenex, in partnership with Mayo Clinic, aims to revolutionize treatment options for individuals with type 2 diabetes (T2D). Endogenex’s innovations focus on resetting the body’s metabolic signaling system by harnessing its natural regenerative capabilities to improve metabolic function. Through the development of the ReCET™ System and the novel application of precise, controlled, non-thermal pulsed electric fields, Endogenex is establishing a new era in treatment options for people living with T2D, helping patients regain control of their blood glucose levels and slow disease progression.
Endogenex is a privately held, clinical-stage company based in Minneapolis, MN.
- Industry Medical Equipment Manufacturing
- Website https://www.endogenex.com/
- LinkedIn https://www.linkedin.com/company/endogenexinc/
OpenBox AI | $5,000,000 | (Mar 31, 2026)
Qodo | $70,000,000 | (Mar 31, 2026)
Starcloud | $170,000,000 | (Mar 31, 2026)
Valinor(1) | $25,000,000 | (Mar 31, 2026)
Mars Men | $27,500,000 | (Mar 31, 2026)
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)